drugset / Trial / NCT00483184
Low Dose Interferon Alpha Treatment for Oral Ulcers of Behcet's Disease
Phase 2
Completed
84 enrolled
Nobel Pharmaceuticals
Ainos, Inc. (f/k/a Amarillo Biosciences Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine the safety and efficacy of natural human interferon alpha (IFN alpha) on size, number, incidence and pain of oral ulcers associated with Behçet's Disease (BD).
Timeline
- Start
- 2006-04
- Primary completion
- 2008-04
- Completion
- 2008-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | 500 iu | Oral |
| Subject | interferon alfa-2b | Protein / enzyme biologic | 1000 iu | Oral |